Targeting the AAA ATPase p97 as an Approach to Treat Cancer through Disruption of Protein Homeostasis

Cancer Cell

Volumn 28, Issue 5, 2015, Pages 653-665

  Anderson, Daniel J ^a   Le Moigne, Ronan ^a   Djakovic, Stevan ^a   Kumar, Brajesh ^a   Rice, Julie ^a   Wong, Steve ^a   Wang, Jinhai ^a   Yao, Bing ^a   Valle, Eduardo ^a   Kiss von Soly, Szerenke ^a   Madriaga, Antonett ^a   Soriano, Ferdie ^a   Menon, Mary Kamala ^a   Wu, Zhi Yong ^a   Kampmann, Martin ^b   Chen, Yuwen ^b   Weissman, Jonathan S ^b   Aftab, Blake T ^c   Yakes, F Michael ^a   Shawver, Laura ^a   Zhou, Han Jie ^a   Wustrow, David ^a   Rolfe, Mark ^a   more..

^a Cleave Biosciences Inc ^*  (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BAFILOMYCIN A1; BORTEZOMIB; CARFILZOMIB; CB 5083; CHLORMETHINE; IXAZOMIB; IXAZOMIB CITRATE; PROTEIN INHIBITOR; PROTEIN P97; THAPSIGARGIN; TUNICAMYCIN; UBIQUITINATED PROTEIN; UNCLASSIFIED DRUG; ADENOSINE TRIPHOSPHATASE; CB-5083; ENZYME INHIBITOR; INDOLE DERIVATIVE; NUCLEAR PROTEIN; P97 ATPASE; PYRIMIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; COLON CANCER; CONTROLLED STUDY; DRUG TARGETING; ENDOPLASMIC RETICULUM ASSOCIATED DEGRADATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MANTLE CELL LYMPHOMA; MOUSE; MULTIPLE MYELOMA; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN HOMEOSTASIS; SOLID TUMOR; TUMOR CELL; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; CRISPR CAS SYSTEM; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; HCT116 CELL LINE; HEK293 CELL LINE; HOMEOSTASIS; K562 CELL LINE; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; NUDE MOUSE; PROCEDURES; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SCID MOUSE; TUMOR CELL LINE; WESTERN BLOTTING;

ADENOSINE TRIPHOSPHATASES; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CRISPR-CAS SYSTEMS; ENDOPLASMIC RETICULUM-ASSOCIATED DEGRADATION; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HEK293 CELLS; HOMEOSTASIS; HUMANS; INDOLES; K562 CELLS; MICE, NUDE; MICE, SCID; MOLECULAR STRUCTURE; MOLECULAR TARGETED THERAPY; NEOPLASMS; NUCLEAR PROTEINS; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; UBIQUITINATED PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84946545972     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2015.10.002     Document Type: Article

References (56)

1. Barretina J., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehár J., Kryukov G.V., Sonkin D., et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012, 483:603-607.
2. Bence N.F., Sampat R.M., Kopito R.R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 2001, 292:1552-1555.
3. Benjamini Y., Yekutieli D. The control of the false discovery rate in multiple testing under dependency. Ann. Stat. 2001, 29:1165-1188.
4. Bjørkøy G., Lamark T., Johansen T. p62/SQSTM1: a missing link between protein aggregates and the autophagy machinery. Autophagy 2006, 2:138-139.
5. Bucheit A.D., Davies M.A. Emerging insights into resistance to BRAF inhibitors in melanoma. Biochem. Pharmacol. 2014, 87:381-389.
6. Bug M., Meyer H. Expanding into new markets-VCP/p97 in endocytosis and autophagy. J. Struct. Biol. 2012, 179:78-82.
7. Chou T.-F., Brown S.J., Minond D., Nordin B.E., Li K., Jones A.C., Chase P., Porubsky P.R., Stoltz B.M., Schoenen F.J., et al. Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathways. Proc. Natl. Acad. Sci. U S A 2011, 108:4834-4839.
8. Chou T.-F., Li K., Frankowski K.J., Schoenen F.J., Deshaies R.J. Structure-activity relationship study reveals ML240 and ML241 as potent and selective inhibitors of p97 ATPase. ChemMedChem 2013, 8:297-312.
9. Cillo C., Dick J.E., Ling V., Hill R.P. Generation of drug-resistant variants in metastatic B16 mouse melanoma cell lines. Cancer Res. 1987, 47:2604-2608.
10. Cole A., Wang Z., Coyaud E., Voisin V., Gronda M., Jitkova Y., Mattson R., Hurren R., Babovic S., Maclean N., et al. Inhibition of the mitochondrial protease ClpP as a therapeutic strategy for human acute myeloid leukemia. Cancer Cell 2015, 27:864-876.
11. Dalal S., Rosser M.F., Cyr D.M., Hanson P.I. Distinct roles for the AAA ATPases NSF and p97 in the secretory pathway. Mol. Biol. Cell 2004, 15:637-648.
12. Dasgupta B., Yi Y., Chen D.Y., Weber J.D., Gutmann D.H. Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. Cancer Res. 2005, 65:2755-2760.
13. DeLaBarre B., Christianson J.C., Kopito R.R., Brunger A.T. Central pore residues mediate the p97/VCP activity required for ERAD. Mol. Cell 2006, 22:451-462.
14. Deshaies R.J. Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy. BMC Biol. 2014, 12:94.
15. Fang C.J., Gui L., Zhang X., Moen D.R., Li K., Frankowski K.J., Lin H.J., Schoenen F.J., Chou T.F. Evaluating p97 inhibitor analogues for their domain selectivity and potency against the p97-p47 complex. ChemMedChem 2015, 10:52-56.
16. Fessart D., Marza E., Taouji S., Delom F., Chevet E. P97/CDC-48: proteostasis control in tumor cell biology. Cancer Lett. 2013, 337:26-34.
17. Flynn A., Vries R.G., Proud C.G. Signalling pathways which regulate eIF4E. Biochem. Soc. Trans. 1997, 25:192S.
18. Gilbert L.A., Horlbeck M.A., Adamson B., Villalta J.E., Chen Y., Whitehead E.H., Guimaraes C., Panning B., Ploegh H.L., Bassik M.C., et al. Genome-scale CRISPR-mediated control of gene repression and activation. Cell 2014, 159:647-661.
19. Hideshima T., Richardson P., Chauhan D., Palombella V.J., Elliott P.J., Adams J., Anderson K.C. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001, 61:3071-3076.
20. Johnson D.E. The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors. Endocr. Relat. Cancer 2015, 22:T1-T17.
21. Ju J.S., Fuentealba R.A., Miller S.E., Jackson E., Piwnica-Worms D., Baloh R.H., Weihl C.C. Valosin-containing protein (VCP) is required for autophagy and is disrupted in VCP disease. J. Cell Biol. 2009, 187:875-888.
22. Kupperman E., Lee E.C., Cao Y., Bannerman B., Fitzgerald M., Berger A., Yu J., Yang Y., Hales P., Bruzzese F., et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res. 2010, 70:1970-1980.
23. Lu M., Lawrence D.A., Marsters S., Acosta-Alvear D., Kimmig P., Mendez A.S., Paton A.W., Paton J.C., Walter P., Ashkenazi A. Cell death. Opposing unfolded-protein-response signals converge on death receptor 5 to control apoptosis. Science 2014, 345:98-101.
24. Luo J., Solimini N.L., Elledge S.J. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009, 136:823-837.
25. Magnaghi P., D'Alessio R., Valsasina B., Avanzi N., Rizzi S., Asa D., Gasparri F., Cozzi L., Cucchi U., Orrenius C., et al. Covalent and allosteric inhibitors of the ATPase VCP/p97 induce cancer cell death. Nat. Chem. Biol. 2013, 9:548-556.
26. Meacham C.E., Morrison S.J. Tumour heterogeneity and cancer cell plasticity. Nature 2013, 501:328-337.
27. Meerang M., Ritz D., Paliwal S., Garajova Z., Bosshard M., Mailand N., Janscak P., Hübscher U., Meyer H., Ramadan K. The ubiquitin-selective segregase VCP/p97 orchestrates the response to DNA double-strand breaks. Nat. Cell Biol. 2011, 13:1376-1382.
28. Meyer H., Bug M., Bremer S. Emerging functions of the VCP/p97 AAA-ATPase in the ubiquitin system. Nat. Cell Biol. 2012, 14:117-123.
29. Milano A., Perri F., Caponigro F. The ubiquitin-proteasome system as a molecular target in solid tumors: an update on bortezomib. Onco Targets Ther. 2009, 2:171-178.
30. Miura G. ER stress: to live or let die. Nat. Chem. Biol. 2014, 10. 695-695.
31. Morris J.A., Dorner A.J., Edwards C.A., Hendershot L.M., Kaufman R.J. Immunoglobulin binding protein (BiP) function is required to protect cells from endoplasmic reticulum stress but is not required for the secretion of selective proteins. J. Biol. Chem. 1997, 272:4327-4334.
32. Morris L.L., Hartman I.Z., Jun D.J., Seemann J., DeBose-Boyd R.A. Sequential actions of the AAA-ATPase valosin-containing protein (VCP)/p97 and the proteasome 19 S regulatory particle in sterol-accelerated, endoplasmic reticulum (ER)-associated degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J. Biol. Chem. 2014, 289:19053-19066.
33. Nguyen T.K., Grant S. Dinaciclib (SCH727965) inhibits the unfolded protein response through a CDK1- and 5-dependent mechanism. Mol. Cancer Ther. 2014, 13:662-674.
34. Oda Y., Okada T., Yoshida H., Kaufman R.J., Nagata K., Mori K. Derlin-2 and Derlin-3 are regulated by the mammalian unfolded protein response and are required for ER-associated degradation. J. Cell Biol. 2006, 172:383-393.
35. Ogata M., Hino S., Saito A., Morikawa K., Kondo S., Kanemoto S., Murakami T., Taniguchi M., Tanii I., Yoshinaga K., et al. Autophagy is activated for cell survival after endoplasmic reticulum stress. Mol. Cell. Biol. 2006, 26:9220-9231.
36. Oromendia A.B., Amon A. Aneuploidy: implications for protein homeostasis and disease. Dis. Model. Mech. 2014, 7:15-20.
37. Patricelli M.P., Nomanbhoy T.K., Wu J., Brown H., Zhou D., Zhang J., Jagannathan S., Aban A., Okerberg E., Herring C., et al. In situ kinase profiling reveals functionally relevant properties of native kinases. Chem. Biol. 2011, 18:699-710.
38. Rabinovich E., Kerem A., Fröhlich K.U., Diamant N., Bar-Nun S. AAA-ATPase p97/Cdc48p, a cytosolic chaperone required for endoplasmic reticulum-associated protein degradation. Mol. Cell. Biol. 2002, 22:626-634.
39. Ramos P., Bentires-Alj M. Mechanism-based cancer therapy: resistance to therapy, therapy for resistance. Oncogene 2014, 34:3617-3626.
40. Ruschak A.M., Slassi M., Kay L.E., Schimmer A.D. Novel proteasome inhibitors to overcome bortezomib resistance. J. Natl. Cancer Inst. 2011, 103:1007-1017.
41. Sano R., Reed J.C. ER stress-induced cell death mechanisms. Biochim. Biophys. Acta 2013, 1833:3460-3470.
42. Schenone S., Brullo C., Musumeci F., Radi M., Botta M. ATP-competitive inhibitors of mTOR: an update. Curr. Med. Chem. 2011, 18:2995-3014.
43. Song C., Wang Q., Li C.C. ATPase activity of p97-valosin-containing protein (VCP). D2 mediates the major enzyme activity, and D1 contributes to the heat-induced activity. J. Biol. Chem. 2003, 278:3648-3655.
44. Song B.L., Sever N., DeBose-Boyd R.A. Gp78, a membrane-anchored ubiquitin ligase, associates with Insig-1 and couples sterol-regulated ubiquitination to degradation of HMG CoA reductase. Mol. Cell 2005, 19:829-840.
45. Teicher B.A., Ara G., Herbst R., Palombella V.J., Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clin. Cancer Res. 1999, 5:2638-2645.
46. Van Drie J.H. Protein folding, protein homeostasis, and cancer. Chin. J. Cancer 2011, 30:124-137.
47. Wacker S.A., Houghtaling B.R., Elemento O., Kapoor T.M. Using transcriptome sequencing to identify mechanisms of drug action and resistance. Nat. Chem. Biol. 2012, 8:235-237.
48. Wang Y., Serradell N., Bolos J., Rosa E. YM-155: apoptosis inducer survivin expression inhibitor oncolytic. Drugs Future 2007, 32:879-882.
49. Wang Q., Mora-Jensen H., Weniger M.A., Perez-Galan P., Wolford C., Hai T., Ron D., Chen W., Trenkle W., Wiestner A., Ye Y. ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells. Proc. Natl. Acad. Sci. USA 2009, 106:2200-2205.
50. Wang Q., Shinkre B.A., Lee J.G., Weniger M.A., Liu Y., Chen W., Wiestner A., Trenkle W.C., Ye Y. The ERAD inhibitor Eeyarestatin I is a bifunctional compound with a membrane-binding domain and a p97/VCP inhibitory group. PLoS ONE 2010, 5:e15479.
51. Wright J.J. Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy. Clin. Cancer Res. 2010, 16:4094-4104.
52. Wustrow D., Zhou H.-J., Rolfe M. Inhibition of ubiquitin proteasome system enzymes for anticancer therapy. Annual Reports in Medicinal Chemistry 2013, 205-225. Academic Press. C.D. Manoj (Ed.).
53. Yamamoto A., Tagawa Y., Yoshimori T., Moriyama Y., Masaki R., Tashiro Y. Bafilomycin A1 prevents maturation of autophagic vacuoles by inhibiting fusion between autophagosomes and lysosomes in rat hepatoma cell line, H-4-II-E cells. Cell Struct. Funct. 1998, 23:33-42.
54. Ye Y., Meyer H.H., Rapoport T.A. The AAA ATPase Cdc48/p97 and its partners transport proteins from the ER into the cytosol. Nature 2001, 414:652-656.
55. Yoshida H., Okada T., Haze K., Yanagi H., Yura T., Negishi M., Mori K. ATF6 activated by proteolysis binds in the presence of NF-Y (CBF) directly to the cis-acting element responsible for the mammalian unfolded protein response. Mol. Cell. Biol. 2000, 20:6755-6767.
56. Zhang L., Pham L.V., Newberry K.J., Ou Z., Liang R., Qian J., Sun L., Blonska M., You Y., Yang J., et al. In vitro and in vivo therapeutic efficacy of carfilzomib in mantle cell lymphoma: targeting the immunoproteasome. Mol. Cancer Ther. 2013, 12:2494-2504.